Voyager Therapeutics (VYGR) Receives News Impact Rating of 0.00

News coverage about Voyager Therapeutics (NASDAQ:VYGR) has trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Voyager Therapeutics earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.8868153830237 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up $0.17 during trading hours on Monday, reaching $13.60. 1,005,100 shares of the company were exchanged, compared to its average volume of 223,100. Voyager Therapeutics has a 52 week low of $8.10 and a 52 week high of $25.99.

Several analysts have recently weighed in on VYGR shares. Wedbush reaffirmed a “positive” rating and set a $31.00 price target (down previously from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity started coverage on shares of Voyager Therapeutics in a research note on Friday, October 27th. They set a “buy” rating and a $35.00 price target for the company. Zacks Investment Research downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, ValuEngine downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $28.89.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.themarketsdaily.com/2017/11/13/voyager-therapeutics-vygr-receives-news-impact-rating-of-0-00.html.

In related news, insider Bernard Ravina sold 16,470 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 38,430 shares of company stock valued at $562,890 in the last three months. 8.00% of the stock is currently owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply